Experimental Drug TOFA Promotes Fat Loss in Obese Mice Without Reducing Food Intake
Research published in Science Advances highlights the potential of an experimental compound known as 5-tetradecyloxy-2-furoic acid (TOFA) in promoting fat loss in obese mice without altering their appetite or food consumption. This innovative approach may offer a new avenue for tackling obesity by not only reducing caloric intake but also enhancing the body's energy expenditure. In a study conducted by a team at the University of California, Berkeley, obese male mice were administered TOFA twice daily for four weeks while being fed a high-fat diet. Remarkably, the mice experienced an average weight loss of 18 percent, primarily from body fat, while their muscle mass remained largely intact. Senior author Anders Näär, a metabolic biologist at UC Berkeley, noted that despite unchanged food intake and physical activity levels, the overall energy expenditure of the mice increased by as much as 18 percent. This increase in energy expenditure appears to stem from TOFA's dual action: it slows down the production of new fat while simultaneously enhancing the cells' ability to burn fat for energy. However, the exact cellular mechanisms contributing to this increased energy expenditure are still not fully understood. The researchers attempted to replicate TOFA's effects through two separate methods—one aimed at reducing fat production and the other at boosting fat burning—but these combinations did not yield the same results as TOFA alone. This suggests that the unique properties of TOFA may play a crucial role in its effectiveness. Beyond weight loss, TOFA also demonstrated additional health benefits, including reductions in blood sugar and insulin levels, improved glucose response, and decreased fat accumulation in the blood and liver. Notably, TOFA did not directly protect muscle tissue; rather, the weight loss observed was predominantly from fat, as the mice maintained their normal eating habits. The study further explored the effects of combining lower doses of TOFA with GLP-1-based drugs, such as semaglutide and tirzepatide, which primarily promote weight loss by reducing appetite. The combination therapies resulted in greater weight loss and metabolic improvements than any single treatment. This dual-action approach—where one treatment reduces energy intake while the other enhances energy expenditure—could offer a complementary strategy for obesity management. Interestingly, TOFA-treated mice were able to maintain their weight for a longer duration after treatment cessation, unlike those treated with semaglutide, who quickly regained weight as their food intake increased. However, it is important to note that these combination experiments were limited in scope, involving small groups of male mice, leaving questions about the effects of TOFA in female subjects unanswered. TOFA has not yet been tested in humans, and its safety and effective dosing remain unknown. The researchers plan to conduct further studies in rats and larger animals before progressing to human clinical trials. While TOFA is not currently a weight-loss treatment, the findings suggest that it may be possible to facilitate fat loss by modifying how the body utilizes energy, rather than solely relying on dietary restrictions. The study was published in Science Advances, and the research team includes co-founders of ReRx Therapeutics, which is developing TOFA as a potential treatment.




